Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms ...

The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...

And Alcon Laboratories issued a voluntary nationwide recall of certain Systane Lubricant Eye Drops due to fungal ...

The platform is designed to highlight the impact of OAB symptoms and educate on disease management, including information on treatment options, such as GEMTESA® (vibegron). In this exclusive with ...

根据住友制药美国公司 (SMPA) 发布的新闻稿，FDA 批准 vibegron (Gemtesa；住友制药美国公司)，这是一种每日服用一次的 β-3 (β 3 ) 肾上腺素能受体激动剂，用于治疗患有膀胱过度活动症 (OAB) ...

1 In the third year of the campaign, Holly partnered with real-life patients Diane and Dar, who are part of the GEMTESA Go-Getters patient ambassador program, to have a candid conversation about ...

Sumitomo Pharma is experiencing a strong growth trajectory, with a notable revenue increase to ¥180.7 billion, driven by successful products like ORGOVYX and GEMTESA, particularly in North America.

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA ...

根据住友制药美国公司 (SMPA) 发布的新闻稿，FDA 批准 vibegron (Gemtesa；住友制药美国公司)，这是一种每日服用一次的 β-3 (β 3 ) 肾上腺素能受体激动剂 ...